HTB

CROI 29 (Retrovirus) 2022

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports

CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports

CROI 2022: Webcasts now online and open access

CROI 2022: Islatravir studies for HIV treatment and PrEP

CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART

CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa

CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses

CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART

CROI 2022: UK study shows PEP is started earlier using home starter packs

29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports

CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies

CROI 2022: Injectable CAB/RPV-LA results after three years follow-up

CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study

CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques

CROI 2022: Fourth potential stem cell HIV cure – in a US woman using donor cord cells

CROI 2022: Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs

CROI 2022: Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study

CROI 2022: AAV8-VRC07 vaccine generates new bNAb production in HIV positive people for up to three years

CROI 2022: Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana

CROI 2022: ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV

CROI 2022: Other studies on anal cancer

CROI 2022: Telomere shortening associated with TAF but not TDF in CHARTER study

CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access

CROI 2022: LEAP Workshop online: research into long-acting drugs

CROI 2022 to only be virtual: programme online